Management of Patients With Follicular Lymphoma Treated First Line With Obinutuzumab

Asia-Pacific Journal of Clinical Oncology - United Kingdom
doi 10.1111/ajco.13153
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Pcn133 - The Societal Impact of Obinutuzumab in the First Line Treatment of Patients With Follicular Lymphoma in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

M7‐FLIPI Is Not Prognostic in Follicular Lymphoma Patients With First‐line Rituximab Chemo‐free Therapy

British Journal of Haematology
Hematology
2019English

Stratification of Patients With Follicular Lymphoma

2012English

Sakk 35/15: A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Pcn141 - Cost-Effectiveness Analysis of Obinutuzumab for the Treatment of Patients With Previously Untreated Advanced Follicular Lymphoma in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Do We Need Maintenance With Anti-Cd20 Antibody After First-Line Therapy for All Newly Diagnosed Follicular Lymphoma Patients?

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2018English

A Retrospective Study on the Management of Patients With Rituximab Refractory Follicular Lymphoma

British Journal of Haematology
Hematology
2017English

Characteristics and Outcomes of Patients With Relapsed Follicular Lymphoma Following Retreatment With Second-Line Rituximab-Containing Chemotherapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy